Janssen details new disease areas, deals for DIA

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) said its Disease Interception Accelerator (DIA) will explore three new disease areas: chronic obstructive pulmonary disease (COPD), gestational diabetes and oropharyngial and cervical cancers. Janssen also released details about research collaborations in those areas.

Janssen launched the DIA last year to predict and prevent progression to disease. The R&D group had previously disclosed three disease areas: Type I diabetes, perinatal depression, and presbyopia and cataracts. ...